Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.

Journal article

Early Breast Cancer Trialists' Collaborative Group (EBCTCG) None., (2018), Lancet Oncol, 19, 27 - 39

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.

Journal article

Pan H. et al, (2017), N Engl J Med, 377, 1836 - 1846

10 vs 5 years of adjuvant tamoxifen: exclusion of 1/402 centres in ATLAS.

Journal article

Davies C. et al, (2017), Lancet, 389

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.

Journal article

Early Breast Cancer Trialists' Collaborative Group (EBCTCG) None., (2015), Lancet, 386, 1353 - 1361

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.

Journal article

Early Breast Cancer Trialists' Collaborative Group (EBCTCG) None., (2015), Lancet, 386, 1341 - 1352

Risk of stroke from new carotid artery occlusion in the Asymptomatic Carotid Surgery Trial-1.

Journal article

den Hartog AG. et al, (2013), Stroke, 44, 1652 - 1659